PharmaMar
Spanish biopharmaceutical company developing and commercializing medicines derived primarily from marine organisms, with a focus on oncology.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
PharmaMar is a Spanish biopharmaceutical company headquartered in Colmenar Viejo, Madrid. Its distinctive research model is based on discovering bioactive compounds in marine organisms and translating them into medicines, particularly for cancer treatment. The company emerged in 1986 as a subsidiary of the Spanish industrial and pharmaceutical group Zeltia, founded to investigate antitumor compounds from marine resources such as tunicates, mollusks and other marine invertebrates. This origin gave PharmaMar a specialized position within oncology: rather than competing primarily through large portfolios of conventional small-molecule medicines, it built its identity around marine biodiversity, natural-product chemistry and oncology-focused clinical development. The company’s best-known medicine is trabectedin, marketed as Yondelis. PharmaMar developed a synthetic production route for the compound, originally identified in a marine tunicate, and advanced it as a treatment for certain advanced soft-tissue sarcomas and ovarian cancer. Yondelis became a landmark product because it was the first fully developed Spanish-origin anticancer medicine to achieve broad regulatory approval. Its development also established the company’s commercial and partnering model: PharmaMar has worked with larger pharmaceutical companies and regional partners to support regulatory filings, manufacturing, distribution and commercialization in different territories. PharmaMar’s portfolio later expanded to include lurbinectedin, marketed in the United States as Zepzelca for a specific indication in metastatic small-cell lung cancer, subject to the applicable regulatory status and confirmatory-development requirements. The company has also developed other marine-derived oncology candidates, including plitidepsin, known commercially as Aplidin in certain contexts, although regulatory availability and approved indications vary by jurisdiction. Its pipeline has included programs directed at solid tumors, hematological malignancies and other difficult-to-treat cancers. The corporate group has operated beyond branded oncology medicines. Genomica, a group subsidiary, has worked in molecular diagnostics, including genetic analysis, paternity testing and infectious-disease testing. During the COVID-19 pandemic, Genomica developed and marketed a molecular diagnostic kit based on its existing diagnostic capabilities. Sylentis, another subsidiary, has pursued treatments using gene-silencing technologies, including RNA interference. These businesses broadened PharmaMar’s capabilities into diagnostics and advanced therapeutics while retaining a strong biotechnology orientation. A major corporate turning point came in 2015, when PharmaMar absorbed Zeltia and its subsidiaries through a reverse merger. The transaction concentrated the group’s identity and listed-company structure around PharmaMar and reflected a strategic decision to focus more directly on pharmaceutical and biotechnology activities. The group subsequently divested or sold several non-core businesses, including the Xylacel wood-treatment brand and Zelnova, helping sharpen its profile as a biopharmaceutical company. PharmaMar’s positioning combines marine natural-product discovery, proprietary chemistry, oncology clinical development and partnership-led commercialization. Its competitive differentiation rests on access to unusual biological compounds, specialized know-how in their isolation and synthesis, and a portfolio aimed at areas of high unmet medical need. At the same time, the business remains exposed to the long timelines, regulatory uncertainty, manufacturing complexity and commercial risks typical of oncology drug development. The company operates internationally through direct activities and licensing or commercialization arrangements, while its research and corporate base remain centered in Spain.
History
PharmaMar’s roots lie in Zeltia, a Spanish group established in Vigo in 1939 as a spin-off from the Miguel Servet laboratories. Zeltia initially operated across several areas of health and applied chemistry, producing medicines associated with cardiovascular, metabolic and gynecological conditions. It later created subsidiaries covering agriculture, pharmaceuticals and chemical-veterinary products. In 1963, Zeltia became publicly traded on the Madrid stock exchange, establishing the listed corporate platform from which its later biotechnology activities developed. The group’s move toward marine biotechnology began in 1986, when José María Fernández Sousa-Faro founded PharmaMar as a Zeltia subsidiary. The new company was created to discover and develop antitumor medicines from marine organisms and related natural resources. This was an unusual strategy at the time: marine ecosystems offered a largely underexplored source of complex molecules, but converting those discoveries into medicines required advanced collection, purification, chemical characterization and manufacturing capabilities. A significant milestone came in 1991, when Zeltia entered genetic and molecular diagnostics through the creation of PharmaGen. That business was renamed Genomica in 2001 and later became associated with genetic analysis, paternity testing and infectious-disease diagnostics. In parallel, PharmaMar advanced its oncology research. In 2001, it completed a chemical synthesis route for trabectedin, also known as ET-743, a compound first identified from a marine tunicate. The ability to produce the compound synthetically was important for development and commercial supply because natural extraction alone would not provide a practical manufacturing basis. Trabectedin was subsequently developed under the Yondelis brand. Regulatory approvals in Europe and the United States supported its use in specified advanced cancers, including soft-tissue sarcoma and ovarian cancer. Yondelis became a defining achievement for PharmaMar and for Spain’s pharmaceutical sector: it was widely recognized as the first anticancer medicine developed entirely in Spain to reach the market. Commercialization involved partnerships and territory-specific arrangements, allowing the company to use the resources of larger pharmaceutical organizations while retaining its discovery and development identity. Zeltia continued broadening its biotechnology portfolio. It established Sylentis in 2006 to develop therapies based on gene-silencing technologies such as RNA interference. The wider group also expanded its European presence during the period from 2012 to 2015, with activities or subsidiaries in countries including Italy, Germany, France and the United Kingdom. This expansion coincided with a growing effort to make pharmaceutical and biotechnology activities the center of the group’s future. In 2015, PharmaMar absorbed Zeltia and its subsidiaries in a reverse merger. The transaction reorganized the listed group around PharmaMar and gave the company a more unified identity. Afterward, the group continued to simplify its portfolio. It sold the Xylacel wood-treatment brand to AkzoNobel in 2018 and divested Zelnova in 2019. These transactions reduced the importance of legacy chemical and consumer-facing businesses and reinforced PharmaMar’s profile as an oncology-centered biopharmaceutical company. The company’s later development included lurbinectedin, marketed in the United States as Zepzelca for a specified small-cell lung cancer indication, and continued work on marine-derived compounds such as plitidepsin. PharmaMar also maintained research programs in other cancers and advanced therapeutic areas. During the COVID-19 pandemic, Genomica used its molecular-diagnostics expertise to develop a coronavirus testing kit, demonstrating that the group’s capabilities extended beyond drug discovery. Today, PharmaMar is an active Spanish public biopharmaceutical company with headquarters in the Madrid area and international activities conducted through its own operations and commercial partnerships. Its corporate identity remains closely connected to marine natural products, oncology and specialized biotechnology. Its history reflects a transition from a diversified industrial group’s pharmaceutical subsidiary to a focused, independently recognized drug-development company.
- 2020
IBEX 35 inclusion
[1]PharmaMar entered the IBEX 35 after previously being part of the IBEX Small Cap index.
- 2019
Zelnova is divested
[1]PharmaMar sold Zelnova as part of its concentration on pharmaceutical and biotechnology businesses.
- 2018
Xylacel is sold
[1]The group sold the Xylacel wood-treatment brand to AkzoNobel.
- 2015
Reverse merger with Zeltia
[1]PharmaMar absorbed Zeltia and its subsidiaries, consolidating the group under the PharmaMar identity.
- 2006
Sylentis is founded
[1]The group created Sylentis to develop gene-silencing therapies based on technologies including RNA interference.
- 2001
Trabectedin synthesis route completed
[1]PharmaMar completed a chemical synthesis route for trabectedin, supporting the development of its leading oncology medicine.
- 1991
Entry into molecular diagnostics
[1]Zeltia created PharmaGen, the predecessor of Genomica, to enter genetic and molecular diagnostic testing.
- 1986
PharmaMar is established
[1]José María Fernández Sousa-Faro founded PharmaMar as a Zeltia subsidiary to develop anticancer medicines from marine-derived resources.
- 1963
Zeltia lists on the Madrid stock exchange
[1]The parent group became publicly traded in Madrid, creating the listed structure that later supported PharmaMar’s development.
- 1939
Zeltia is founded
[1]Zeltia was established in Vigo as a spin-off from the Miguel Servet laboratories and initially focused on pharmaceutical and chemical products.
Products and positioning
A specialized oncology biopharmaceutical company built around marine-derived natural products, proprietary drug discovery and development, and international licensing partnerships.
Oncology medicine
Yondelis
Yondelis is the brand name for trabectedin, a marine-derived anticancer compound originally identified from a sea tunicate. PharmaMar developed a synthetic production route and advanced the drug through clinical development. It has been approved in specified jurisdictions and indications for advanced soft-tissue sarcoma and ovarian cancer, with exact labeling dependent on the relevant regulator. Yondelis is the product most closely associated with PharmaMar’s emergence as an internationally recognized oncology company.
Oncology medicine
Zepzelca
Zepzelca is the commercial name for lurbinectedin, a synthetic oncology compound developed by PharmaMar. In the United States it received authorization for a specified indication involving metastatic small-cell lung cancer after progression on or following platinum-based chemotherapy. Its development expanded PharmaMar’s commercial oncology portfolio beyond trabectedin and reflected the company’s continued focus on cancers with limited treatment options.
Investigational oncology medicine
Aplidin
Aplidin is associated with plitidepsin, a marine-derived compound investigated by PharmaMar for anticancer uses and other potential applications. The compound has been studied in hematological and solid-tumor settings, but regulatory approval, availability and indication differ by jurisdiction. It is part of PharmaMar’s broader marine-natural-product research platform rather than a universally approved global product.
Molecular diagnostics
Genomica diagnostic tests
Genomica develops molecular diagnostic procedures and testing products, including genetic analysis and paternity-testing services in Spain. Its capabilities also cover infectious-disease diagnostics. During the COVID-19 pandemic, the subsidiary developed a coronavirus molecular diagnostic kit based on technologies used in its existing testing business.
Advanced therapeutics · 2006
Sylentis gene-silencing programs
Sylentis is PharmaMar’s subsidiary focused on gene-silencing therapies, including RNA-interference approaches. Its programs seek to regulate disease-related gene expression rather than rely solely on conventional small-molecule mechanisms. These programs represent a research and development platform within the group and are distinct from PharmaMar’s marketed oncology medicines.
Brand decisions
2020
COVID-19 molecular diagnostic kitProduct launchBackground
The COVID-19 pandemic created urgent demand for molecular testing and allowed Genomica to apply its existing diagnostic expertise to the new coronavirus.
Action taken
Genomica developed a coronavirus diagnostic kit intended to support rapid molecular detection.
Aftermath
The initiative expanded public awareness of PharmaMar’s diagnostics capabilities beyond its oncology medicines.
2019
Divestment of ZelnovaStrategyBackground
Following the earlier sale of Xylacel, PharmaMar continued to exit non-core businesses inherited from the former Zeltia group.
Action taken
PharmaMar sold the Zelnova subsidiary.
Aftermath
The transaction further concentrated PharmaMar’s identity on oncology, biotechnology and related diagnostics.
2018
Sale of the Xylacel brandStrategyBackground
The group was reducing activities outside its core pharmaceutical and biotechnology businesses.
Action taken
PharmaMar sold Xylacel, a wood-treatment brand, to AkzoNobel.
Aftermath
The divestment narrowed the group’s portfolio and reinforced its focus on biopharmaceutical activities.
2015
Consolidation through reverse mergerM&ABackground
Zeltia sought to concentrate the group around its pharmaceutical and biotechnology activities and make PharmaMar the principal corporate identity.
Action taken
PharmaMar absorbed Zeltia and all of its subsidiaries through a reverse merger.
Aftermath
The transaction created a more focused PharmaMar group and established the company as the listed operating center of the former Zeltia organization.
Recent events
- 2020
Genomica develops a COVID-19 molecular diagnostic kit[1]
Product launch · Other
The group’s Genomica subsidiary developed a coronavirus diagnostic kit based on its previous molecular-testing technology, enabling detection before or around the appearance of symptoms.
- 2020
PharmaMar joins the IBEX 35[1]
Other
PharmaMar became a constituent of Spain’s IBEX 35 index after previously being included in the IBEX Small Cap index.
- 2019
PharmaMar divests Zelnova[1]
M&A
PharmaMar sold the Zelnova subsidiary, further reducing exposure to businesses outside its core pharmaceutical and biotechnology focus.
- 2018
PharmaMar sells the Xylacel brand[1]
M&A
The group sold the Xylacel wood-treatment brand to AkzoNobel as part of its continuing concentration on pharmaceutical and biotechnology activities.
- 2015
PharmaMar absorbs Zeltia in a reverse merger[1]
M&A
PharmaMar completed the corporate transaction through which it absorbed Zeltia and the group’s subsidiaries, making PharmaMar the principal listed and operating identity of the combined group.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/pharmamar · Editorial policy · How profiles are compiled